Study is showing promise in reducing cardiovascular events by 20% with high risk patients..BD
Interim results from the ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension) trial demonstrate that high-risk, high blood pressure patients treated with Lotrel(R) (amlodipine besylate and benazepril HCl) had 20% fewer cardiovascular events than those taking a benazepril and hydrochlorothiazide (HCTZ) combination. This is the first cardiovascular outcomes trial in a hypertensive population where all patients were randomized to receive a single-pill combination treatment at the onset of the trial as opposed to a step care regimen. Lotrel is approved for the treatment of high blood pressure. It should not be used before other medications have been tried first.
Lotrel, A Single Pill Combination For Treating High Blood Pressure, Reduced Cardiovascular Events By 20% In High-Risk Patients
Study is showing promise in reducing cardiovascular events by 20% with high risk patients..BD
Lotrel, A Single Pill Combination For Treating High Blood Pressure, Reduced Cardiovascular Events By 20% In High-Risk Patients